Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 6/20 | 0.44 |
| ▸ | METAP1 | P53582 | 4/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 4/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466167 | 0.87 | CES1 (0.46) | DAGLAMETAP2METAP1FAAHERAP2 | |
| SCHEMBL2162943 | 0.81 | FAAH (0.64) | DAGLAFAAHCES1NCEH1 | |
| SCHEMBL6464323 | 0.80 | DAGLA (0.45) | DAGLAFAAH | |
| SCHEMBL800520 | 0.77 | DAGLA (0.47) | DAGLAMMP2HDAC1HDAC8HDAC6 | |
| SCHEMBL6463454 | 0.76 | HDAC1 (0.43) | DAGLAFAAHHDAC1HDAC8HDAC6 | |
| SCHEMBL7735821 | 0.75 | MAPT (0.47) | DAGLAKMT2A | |
| SCHEMBL6062618 | 0.75 | PSMB1 (0.44) | DAGLA | |
| SCHEMBL7042158 | 0.75 | DAGLA (0.42) | DAGLAKMT2A | |
| SCHEMBL15214456 | 0.74 | DAGLA (0.39) | DAGLAHDAC1HDAC8HDAC6 | |
| SCHEMBL7732335 | 0.73 | CES1 (0.49) | DAGLAMETAP2METAP1FAAHERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | DAGLA 2304/4885METAP2 244/4885METAP1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.